<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897594</url>
  </required_header>
  <id_info>
    <org_study_id>TERN201-1007</org_study_id>
    <nct_id>NCT04897594</nct_id>
  </id_info>
  <brief_title>AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Proof of Concept, Adaptive, Phase 1b Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Orally Administered TERN-201 in Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terns, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terns, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b multi-center, randomized, double-blind, dose-ranging, placebo-controlled,&#xD;
      adaptive study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) of&#xD;
      TERN-201 in patients with non-cirrhotic NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Triple</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subject incidence of adverse events for TERN-201 versus placebo</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentration of TERN-201- AUC</measure>
    <time_frame>12 weeks and 6 weeks respectively</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentration of TERN-201- Cmax</measure>
    <time_frame>12 weeks and 6 weeks respectively</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentration of TERN-201- Tmax</measure>
    <time_frame>12 weeks and 6 weeks respectively</time_frame>
    <description>Time to reach maximum measured plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentration of TERN-201- T1/2</measure>
    <time_frame>12 weeks and 6 weeks respectively</time_frame>
    <description>determination of half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from baseline in plasma VAP-1/SSAO activity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Part 1: TERN-201 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally Administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: TERN-201 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Orally administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TERN-201</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Part 1: TERN-201 dose level 1</arm_group_label>
    <arm_group_label>Part 2: TERN-201 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 18 to 75 years of age&#xD;
&#xD;
          -  Overweight or obese with a body mass index (BMI) ≥ 25 kg/m2&#xD;
&#xD;
          -  Presumed NASH based on clinical characteristics or prior liver biopsy&#xD;
&#xD;
          -  ALT ≥ 43 IU/L for men and ≥ 28 IU/L for women&#xD;
&#xD;
          -  MRI-cT1 value&gt; 800 ms&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or clinical evidence of chronic liver diseases other than NAFLD&#xD;
&#xD;
          -  History or clinical evidence of cirrhosis, hepatic decompensation or other severe&#xD;
             liver impairment&#xD;
&#xD;
          -  History of liver transplant, or current placement on a liver transplant list&#xD;
&#xD;
          -  Weight loss of &gt; 5% total body weight within 3 months prior to Screening&#xD;
&#xD;
        Note: Other protocol-defined inclusion/exclusion criteria that apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>clinicaltrials@ternspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Terns, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Terns CLinical Study Site 1018</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1024</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1004</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1039</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1001</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1010</name>
      <address>
        <city>Bastrop</city>
        <state>Louisiana</state>
        <zip>71220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1006</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1003</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terns Clinical Study Site 1019</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular adhesion protein-1(VAP- 1)/ semicarbazide-sensitive amine oxidase (SSAO)</keyword>
  <keyword>Nonalcoholic steatohepatitis (NASH)</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease (NAFLD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

